Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Novo Nordisk A/S’s weight-loss and diabetes drugs ... Novo can now meet the demand for Ozempic and Wegovy nationwide, the Food and Drug Administration said Friday. The ruling shows Novo ...

Novo Nordisk (NVO) ended a five-day losing streak ... rating on the maker of hugely popular obesity/ diabetes drugs, Ozempic and Wegovy. Nine years after starting its coverage, the Paris-based ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

Award-winning musician, Michael Trotter Jr. of The War and Treaty, critically acclaimed chef, Franklin Becker, and entrepreneur and salon owner, Maria, share how they manage their type 2 diabetes ...